Oncotelic Therapeutics, Inc. (OTLC)
OTCMKTS · Delayed Price · Currency is USD
0.0900
-0.0085 (-8.63%)
Oct 8, 2025, 3:59 PM EDT
Oncotelic Therapeutics Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
26
Market Cap
39.36M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 70.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 1.74M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Elite Pharmaceuticals | 105.45M |
| Glass House Brands | 221.55M |
| Veradigm | 588.02M |
| Northwest Biotherapeutics | 1.09M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.17M |
| Jushi Holdings | 256.36M |
| AMJ Global Technology | 39.00 |
Oncotelic Therapeutics News
- 15 hours ago - Sapu Nano Unveils First-in-Human Clinical Trial of Sapu-003 at 8th Australian Translational Breast Cancer Research Symposium - GlobeNewsWire
- 14 days ago - Sapu Nano's Sapu003 Advances to Human Clinical Testing - Transforming Everolimus Delivery with Full Bioavailability for Breast Cancer Patients - GlobeNewsWire
- 16 days ago - IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Vuong Trieu, CEO of Oncotelic Therapeutics Inc. - GlobeNewsWire
- 19 days ago - NetworkNewsAudio Announces Audio Press Release (APR) on Innovation in Cancer, Rare Disease Treatment Space - GlobeNewsWire
- 20 days ago - Oncotelic Therapeutics Inc. (OTCQB: OTLC) Creating Pioneering Pipeline Designed to Transform Cancer, Rare Diseases Treatments - GlobeNewsWire
- 22 days ago - Oncotelic Therapeutics Inc. (OTCQB: OTLC) Building Breakthrough Portfolio Aimed at Transforming Cancer, Rare Disease Treatments - GlobeNewsWire
- 26 days ago - Oncotelic Therapeutics Highlights 2 Years of Clinical and Regulatory Advancements Across Late-Stage Pipeline - GlobeNewsWire
- 4 weeks ago - IBN Initiates Coverage of Oncotelic Therapeutics Inc. - GlobeNewsWire